- Home
- EXEL vs MASI Comparison
EXEL vs MASI Comparison
Compare EXEL & MASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- MASI
- Stock Information
- Founded
- EXEL 1994
- MASI 1989
- Country
- EXEL United States
- MASI United States
- Employees
- EXEL N/A
- MASI N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- MASI Medical/Dental Instruments
- Sector
- EXEL Health Care
- MASI Health Care
- Exchange
- EXEL Nasdaq
- MASI Nasdaq
- Market Cap
- EXEL 10.0B
- MASI 9.3B
- IPO Year
- EXEL 2000
- MASI 2007
- Fundamental
- Price
- EXEL $34.59
- MASI $174.05
- Analyst Decision
- EXEL Buy
- MASI Buy
- Analyst Count
- EXEL 17
- MASI 7
- Target Price
- EXEL $32.18
- MASI $170.67
- AVG Volume (30 Days)
- EXEL 1.7M
- MASI 487.6K
- Earning Date
- EXEL 02-04-2025
- MASI 11-05-2024
- Dividend Yield
- EXEL N/A
- MASI N/A
- EPS Growth
- EXEL 441.02
- MASI N/A
- EPS
- EXEL 1.55
- MASI 1.45
- Revenue
- EXEL $2,081,598,000.00
- MASI $2,042,600,000.00
- Revenue This Year
- EXEL $20.59
- MASI $3.85
- Revenue Next Year
- EXEL $1.50
- MASI $2.26
- P/E Ratio
- EXEL $22.41
- MASI $120.04
- Revenue Growth
- EXEL 17.31
- MASI N/A
- 52 Week Low
- EXEL $19.20
- MASI $101.61
- 52 Week High
- EXEL $36.97
- MASI $180.97
- Technical
- Relative Strength Index (RSI)
- EXEL 51.61
- MASI 58.37
- Support Level
- EXEL $34.30
- MASI $172.93
- Resistance Level
- EXEL $36.22
- MASI $180.97
- Average True Range (ATR)
- EXEL 0.75
- MASI 4.52
- MACD
- EXEL -0.29
- MASI -0.83
- Stochastic Oscillator
- EXEL 25.09
- MASI 36.58
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About MASI Masimo Corporation
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.